Experiences with
Tyrosine757 public posts
Want to take advantage of all our features? Just log in!
or
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
randomized trial with 238 patients, with my emphasis; https://www.medpagetoday.com/meetingcoverage/ashhematology/113337
[i]Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously received a covalent Bruton's tyrosine
LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase. Phase 1 trial results.
Rocbrutinib is a new drug offering hope to patients with what are known as gatekeeper mutations that confer resistance to Pirtobrutinib. This BTKi is unique in being both a covalent and non covalent inhibitor of BTK.
Patients with gatekeeper mutations have poor outcomes and short survival and demonstrate